Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
Lists
Only you see this
Abstract
Background: Despite the survival gain observed with antiPD-1 agents in R/M HNSCC, responses are modest and no predictive biomarkers have been validated. We investigated immune and genomic biomarkers of response in a prospective cohort of R/M HNSCC patients (pts) treated with pembrolizumab 200 mg IV Q3W in the INSPIRE study. Methods: Pts had blood samples (BS) collected at baseline (BL) and on treatment (OT) at cycle 3 (week 9); fresh tumor biopsies (FTB) collected at BL and OT (week 6-9). Analyses included tumor whole exome sequencing and immunophenotyping by flow cytometry of FTB and BS; tumor PD-L1 staining (clone 22C3) using modified proportion score. Response rate (RR) using RECIST 1.1. Median progression-free survival (PFS) and overall survival (OS) estimated by Kaplan-Meier method. Time to progression (TTP) was estimated using cumulative incidence function. Univariable analyses of genomic and immune parameters were conducted to identify response predictors. Results: Seventeen pts were enrolled: median age 62 years (48-71); smoking history > =10 pack-year (PY)= 11; oral cavity=7, oropharynx=6 (5 HPV+), larynx/hypopharynx=4. Platinum-refractory= 15; > = 2 prior lines of therapy= 4; PD-L1 > = 1%= 9. RR = 3 partial responses (PR), 10 stable disease (SD), 4 progressive disease (PD). Median follow-up was 4.9 months (m)(0.6-19.3); TTP 9.7m (3.5-not-reached (NR)), PFS 4m (2.3-9.5); OS 7.9m (3.4-NR). Pts with PR had >10 PY, PD-L1 >50% and no local recurrence. Pts with PR+SD had less proliferating ki67+, FoxP3+ T-regulatory cells (Tregs) in blood compared to PD pts (p0.05). Seven pts had FTB for analysis (1 PR, 3 SD, 3 PD): patient with PR (HPV+ oropharynx) had less immunosuppressive Tregs via lower expression of CTLA-4 and CD39 in BL tumor and increased proliferating Tregs at paired OT FTB. Tumor somatic coding mutation burden and percent genome copy alteration in FTB at BL (N = 9) did not predict response (PR+SD) but a trend was observed with percent loss of heterozygosity (p0.15). Conclusions: This preliminary data suggest peripheral and tumor T-regs might play a critical role in R/M HNSCC pts treated with anti-PD1 agents. Dynamic immune-cell changes were more informative than BL genomic markers. Clinical trial identification: NCT02644369. Legal entity responsible for the study: Princess Margaret Cancer Centre. Funding: Merck Disclosure: A. Spreafico: Consultant and advisory boards: Merck, Bristol-Myers Squibb, Novartis. L.L. Siu: Advisory board: Merck; Funding to institution (Princess Margaret Cancer Centre) to conduct clinical trials: Merck. A. Hansen: Research support: Genentech/Roche, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Boston Biomedical, Boehringer-Ingelheim. All other authors have declared no conflicts of interest.
BibTeX
@article{bernal2018analysis,
author = {M. Oliva Bernal and S. Lien and B.X. Wang and S. Yang and Anna Spreafico and Raymond Jang and Sawako Elston and Scott Jennings and Haiyan Jiang and Benjamin Haibe‐Kains and Trevor J. Pugh and Pamela S. Ohashi and L.L. Siu and Aaron R. Hansen},
title = {{Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study}},
journal = {Annals},
year = {2018},
doi = {10.1093/annonc/mdy287.044},
}Loading related content...